SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
As per letter attached.22-02-2022
22-02-2022
Sun Pharma, DRL have presence in Ukraine; trade worth $2.35 billion
India is Ukraine's fifth largest overall export destination17-02-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting14-02-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 09, 2022 for Raksha Sudhir Valia09-02-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201507-02-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting05-02-2022
Sun Pharma hits six year-high; gains 13% in last eight days on strong Q3
In Q3, the company has witnessed stronger growth than anticipated in the US, Emerging Markets and RoW.04-02-2022
Buy Sun Pharmaceutical Industries; target of Rs 1075: ICICI Direct
ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1075 in its research report dated February 02, 2021.03-02-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Company's Q3FY22 earnings conference call.03-02-2022